Recurrent chromosomal breakpoints in patients with myelodysplastic syndromes and complex karyotype versus fragile sites.
暂无分享,去创建一个
Z. Zemanová | J. Březinová | K. Michalová | J. Čermák | Z. Krejcík | M. Dostalova Merkerova | R. Neuwirtová | M. Šišková | D. Bystřická | O. Černá | I. Sárová | S. Izáková | L. Lizcová | A. Jonášová | D. Bystrická
[1] Y. Pekarsky,et al. Common Fragile Site Tumor Suppressor Genes and Corresponding Mouse Models of Cancer , 2010, Journal of biomedicine & biotechnology.
[2] Thomas H Müller,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.
[3] S. Park,et al. Tumor Necrosis Factor-α Enhances DMSO-Induced Differentiation of HL-60 Cells through Activation of ERK/MAPK Pathway. , 2007 .
[4] Z. Zemanová,et al. Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH. , 2007, Leukemia research.
[5] U. Germing,et al. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. , 2006, Cancer genetics and cytogenetics.
[6] D. B. Sayın,et al. Common fragile sites associated with the breakpoints of chromosomal aberrations in hematologic neoplasms. , 2002, Cancer genetics and cytogenetics.